Economic burden of asthma in Singapore.
asthma
health economist
paediatric asthma
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
28
05
2020
revised:
09
11
2020
accepted:
21
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
25
11
2021
Statut:
ppublish
Résumé
Up-to-date economic burden of asthma in Singapore is currently unknown. We quantify the per capita and total annual costs of asthma for adults and children by level of symptom control (uncontrolled, partly controlled, and well controlled) via a cross-sectional online survey administered to a national web panel. Participants were asked about healthcare utilisation, days missed from work, and reduced productivity due to their symptoms. These values were then monetised and multiplied by prevalence estimates of adult and child asthmatics to generate total costs. A total of 300 adults and 221 parents of children with asthma were included in analysis. The total annual cost of adult asthma was estimated to be SGD 1.74 billion (US$1.25 billion) with 42% coming from the uncontrolled group, 45% from the partly controlled group, and 13% from the well-controlled group. For children, the total cost is SGD 0.35 billion (US$0.25 billion), with 64%, 26% and 10% coming from each group respectively. Combined, the annual economic burden of asthma in Singapore is SGD 2.09 billion (US$1.50 billion) with 79% due to productivity losses. Poorly controlled asthma imposes a significant economic burden. Therefore, better control of disease has the potential to generate not only health improvements, but also medical expenditure savings and productivity gains.
Sections du résumé
BACKGROUND AND OBJECTIVE
Up-to-date economic burden of asthma in Singapore is currently unknown.
METHODS
We quantify the per capita and total annual costs of asthma for adults and children by level of symptom control (uncontrolled, partly controlled, and well controlled) via a cross-sectional online survey administered to a national web panel. Participants were asked about healthcare utilisation, days missed from work, and reduced productivity due to their symptoms. These values were then monetised and multiplied by prevalence estimates of adult and child asthmatics to generate total costs.
RESULTS
A total of 300 adults and 221 parents of children with asthma were included in analysis. The total annual cost of adult asthma was estimated to be SGD 1.74 billion (US$1.25 billion) with 42% coming from the uncontrolled group, 45% from the partly controlled group, and 13% from the well-controlled group. For children, the total cost is SGD 0.35 billion (US$0.25 billion), with 64%, 26% and 10% coming from each group respectively. Combined, the annual economic burden of asthma in Singapore is SGD 2.09 billion (US$1.50 billion) with 79% due to productivity losses.
CONCLUSION
Poorly controlled asthma imposes a significant economic burden. Therefore, better control of disease has the potential to generate not only health improvements, but also medical expenditure savings and productivity gains.
Identifiants
pubmed: 33737309
pii: 8/1/e000654
doi: 10.1136/bmjresp-2020-000654
pmc: PMC7978329
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: EAF: has done paid consulting work for AstraZeneca and other Pharma companies. BO: is an employee of AstraZeneca. However, he had no role in the analysis and AstraZeneca did not have a right of refusal on publication. MSK: has grant support from Astra-Zeneca, and received honoraria for lectures and advisory board meetings paid to her hospital (Singapore General Hospital) from GlaxoSmithKline, Astra-Zeneca, Sanofi, Novartis and Boehringer Ingelheim, outside the submitted work.
Références
J Paediatr Child Health. 2007 May;43(5):353-8
pubmed: 17489824
Respirology. 2013 Aug;18(6):957-67
pubmed: 23730953
Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):787-93
pubmed: 9309994
Health Aff (Millwood). 2001 Nov-Dec;20(6):233-41
pubmed: 11816664
Clin Exp Allergy. 2018 Jun;48(6):650-662
pubmed: 29676834
Allergy Asthma Immunol Res. 2011 Jan;3(1):34-8
pubmed: 21217923
J Allergy Clin Immunol. 2003 Jun;111(6):1212-8
pubmed: 12789219
J Asthma Allergy. 2019 Jul 11;12:183-194
pubmed: 31372003
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Soc Psychiatry Psychiatr Epidemiol. 2013 Aug;48(8):1273-82
pubmed: 23370618
J Allergy Clin Immunol. 2000 Sep;106(3):493-9
pubmed: 10984369
Allergy. 2008 Jan;63(1):116-24
pubmed: 18053021
Int Arch Allergy Immunol. 2006;141(2):189-98
pubmed: 16899987
Respirology. 2017 Apr;22(3):454-459
pubmed: 27862645
BMC Public Health. 2007 May 17;7:82
pubmed: 17509137
Chest. 2006 Jul;130(1 Suppl):4S-12S
pubmed: 16840363
BMC Pulm Med. 2009 May 19;9:24
pubmed: 19454036
J Asthma. 2020 Aug 24;:1-10
pubmed: 32777181
Pharmacoeconomics. 2018 Aug;36(8):957-971
pubmed: 29736895
J Asthma. 2016;53(2):194-200
pubmed: 26377375
Appl Health Econ Health Policy. 2019 Feb;17(1):15-24
pubmed: 30105745
Allergy. 2014 Apr;69(4):501-9
pubmed: 24456108
Eur Respir J. 2005 Jan;25(1):47-53
pubmed: 15640322
Pharmaceuticals (Basel). 2010 Mar 08;3(3):514-540
pubmed: 27713266
CMAJ. 1996 Mar 15;154(6):821-31
pubmed: 8634960
PLoS One. 2016 Jan 11;11(1):e0146003
pubmed: 26751790
J Allergy Clin Immunol. 2003 Feb;111(2):263-8
pubmed: 12589343
J Allergy Clin Immunol. 2017 Feb;139(2):408-414.e2
pubmed: 27979429
Aust N Z J Med. 1999 Apr;29(2):228-33
pubmed: 10342022
NPJ Prim Care Respir Med. 2019 May 3;29(1):16
pubmed: 31053715
Eur Respir J. 1999 Feb;13(2):281-6
pubmed: 10065668